title: Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
abstract: The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma (HL). CD30 is rarely expressed by normal cells and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates. Brentuximab vedotin is the first antibody-drug conjugate to be approved by regulatory agencies for the treatment of patients with relapsed HL, with a single-agent response rate of 75%. In this review article, we discuss the current and ongoing development of brentuximab vedotin in patients with relapsed and newly diagnosed HL.
authors: From the Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
authors: Anna
authors: A
authors: Alperovich
authors: Anas
authors: A
authors: Younes
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000079963:Brentuximab Vedotin; D003131:Combined Modality Therapy; D006689:Hodgkin Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors*; D058990:Molecular Targeted Therapy; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin